UTHR insider sales: 4,000-share Form 144 and 72,000 shares sold in Sept

Rhea-AI Filing Summary

United Therapeutics (UTHR) submitted a Form 144 reporting a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,739,525.20. The filing states 45,230,000 shares outstanding and lists the approximate sale date as 10/02/2025. The shares being offered were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, with 294,000 shares originally received via exercised vested options and payment in common shares. The notice also discloses prior sales by the same person totaling 72,000 shares between 09/09/2025 and 10/01/2025, with daily sales recorded through mid-September to early October. The filer attests no undisclosed material information and the transaction is being executed by a broker on NASDAQ.

Positive

• Transaction routed through a registered broker (TD Securities (USA) LLC), indicating orderly execution
• Filer attests no undisclosed material information in the notice

Negative

• Insider sold 72,000 shares in the past three weeks, which may increase share supply in the short term
• Proposed sale of 4,000 shares continues recent selling activity by the same insider

Insights

Equity Insider Transactions Analyst

TL;DR: An insider is continuing structured sales; proposed sale is small relative to outstanding shares.

What it means: The filing records a proposed sale of 4,000 shares and prior sales of 72,000 shares over three weeks. These transactions were routed through TD Securities on NASDAQ.

Why it matters: Insider sales are material to investors because they show supply pressure and relationship to insider liquidity. The proposed sale equals about 0.0088% of outstanding shares and the three-month total equals about 0.16% of the company's 45,230,000 shares outstanding, indicating the sales are non-trivial for the individual but small relative to total float.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20th Floor NEW YORK NY 10017	4000	1739525.20	45230000	10/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672592.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736488.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/25/2025	4000	1723739.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/26/2025	4000	1712891.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/29/2025	4000	1702526.76
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/30/2025	4000	1691357.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/01/2025	4000	1701796.53

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does United Therapeutics (UTHR) report on this Form 144?

The form reports a proposed sale of 4,000 common shares by an insider through TD Securities, with an aggregate market value of $1,739,525.20 and an approximate sale date of 10/02/2025.

Who is selling the shares disclosed in the filing?

The securities were acquired by Martine Rothblatt on 03/15/2016 under an executive deferred compensation arrangement; sales listed in the filing are attributed to the same person.

How many shares has the insider sold in the past three months?

The filing shows prior sales totaling 72,000 shares between 09/09/2025 and 10/01/2025.

What percentage of outstanding shares do these sales represent?

The filing lists 45,230,000 shares outstanding; the 72,000 shares sold in the past three months represent about 0.16% of outstanding shares.

On which exchange will the proposed sale occur?

The proposed sale is to be executed on NASDAQ via TD Securities (USA) LLC.